Tysabri vs Tremfya for Crohn's Disease: Key Differences

Tysabri and Tremfya represent very different positions in the Crohn's biologic landscape. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for Crohn's in March 2025 based on GALAXI-2, GALAXI-3, and GRAVITI. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs tremfya crohn's comparison.

Integrin vs IL-23 p19 Mechanism

Tysabri binds alpha-4 integrin, blocking lymphocyte trafficking to both gut and brain tissue. Tremfya binds the p19 subunit of interleukin-23, selectively blocking IL-23 signaling while preserving IL-12. IL-23 is a central driver of Th17-mediated inflammation in Crohn's. The natalizumab vs guselkumab distinction is foundational: Tysabri's broad integrin mechanism creates PML risk, while Tremfya's selective IL-23 blockade produces a favorable safety profile.

Crohn's Efficacy

Tremfya's Crohn's efficacy rests on GALAXI-2 and GALAXI-3, two pivotal phase 3 trials that compared guselkumab with placebo and with ustekinumab (Stelara). Tremfya demonstrated statistical superiority over Stelara on endoscopic response at week 48 in pooled analyses. GRAVITI separately evaluated fully subcutaneous induction for guselkumab in Crohn's, demonstrating that patients could skip IV induction entirely and still achieve meaningful response. Tysabri's Crohn's efficacy rests on ENACT-1, ENACT-2, and ENCORE. No head-to-head trial has directly compared Tysabri with Tremfya in Crohn's. Indirect comparisons suggest Tremfya produces strong response in biologic-naive and biologic-experienced Crohn's patients. Tysabri is typically reserved for patients refractory to Tremfya and other biologic classes.

PML Risk and TOUCH Program

Tysabri carries a black-box warning for PML. The TOUCH program requires enrollment, JC virus antibody testing, routine monitoring, and prescriber/pharmacy/infusion center certification. Most gastroenterologists reserve Tysabri for Crohn's patients who have failed multiple other biologic classes and who test negative for JC virus antibodies. Tremfya has no such restricted access program.

Tremfya Safety Profile

Tremfya's Crohn's safety data from GALAXI and GRAVITI has been favorable, consistent with its broader psoriasis and psoriatic arthritis experience. Long-term data for IL-23 p19 biologics consistently shows low rates of serious systemic infection and malignancy. For tysabri vs tremfya side effects, Tremfya is the clear winner for patients with infection concerns, cancer history, or complex comorbidities.

Refractory Crohn's Biologic

For refractory Crohn's patients who have failed anti-TNFs, Stelara, and other biologic classes, both Tysabri and Tremfya can be considered. Tremfya is generally tried first because of its favorable safety profile and head-to-head data against Stelara in GALAXI. Tysabri is reserved for patients who have failed Tremfya and who test JC virus antibody negative.

Administration and Dosing

Tysabri is administered as a 300 mg IV infusion every 4 weeks at a TOUCH-certified infusion center, per Biogen's prescribing information. Tremfya for Crohn's offers a distinctive dual induction pathway. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8) per the GALAXI and GRAVITI programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. For Crohn's patients who want to avoid infusion center visits entirely, Tremfya's SC-only induction option via GRAVITI is a distinctive practical advantage. Tysabri requires lifelong monthly IV infusions at a TOUCH-certified center.

When Tysabri Might Be Considered

For Crohn's patients who have failed multiple biologic classes including Tremfya, Tysabri may be considered, particularly in patients who test negative for JC virus antibodies. This is a narrow population, and shared decision-making with a gastroenterologist experienced in refractory Crohn's is essential.

Anti-TNF Experienced Patients

For Crohn's patients with prior anti-TNF exposure, Tremfya's GALAXI program included biologic-experienced patients and showed meaningful response. Tysabri also has efficacy in biologic-experienced patients, but the PML risk typically drives clinicians to try mechanism-class alternatives like Tremfya, Skyrizi, Omvoh, Stelara, or Entyvio before Tysabri.

Biosimilar Availability

Tremfya is branded with no biosimilar. Tysabri has a biosimilar (Tyruko) approved in 2023, though real-world utilization in IBD remains low given TOUCH program requirements apply equally to biosimilars.

Practical Access

Tremfya can be administered at a variety of infusion centers for induction if IV is chosen, or fully at home if the SC induction pathway is used. Tysabri requires infusion at a TOUCH-certified center. For patients with complex schedules or geographic barriers, Tremfya's accessibility is a major practical advantage.

Choosing With Your GI

For a Crohn's patient deciding between Tysabri and Tremfya, Tremfya is preferred for most patients because of its established efficacy (including head-to-head data against Stelara in GALAXI), favorable safety profile, induction flexibility via GRAVITI, less frequent SC maintenance, and absence of TOUCH program restrictions. Tysabri is a niche option reserved for patients who have exhausted other biologic classes including Tremfya and who test JC virus antibody negative. If you are considering Tysabri, ask your GI about JC virus antibody status, prior treatment history, and the specific risk-benefit rationale. A log of stool frequency, urgency, abdominal pain, and any new neurological symptoms between visits is particularly important for patients on Tysabri.